Longevity Families of the Netherlands

Aging Clinical Trial

— LOF-NL  

Official title:

Longevity Families of the Netherlands

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06374069
• Other study ID #: NL81887.058.23
• Status: Recruiting
• Start date: September 11, 2023
• Est. completion date: December 2026

Study information

• Verified date: April 2024
• Source: Leiden University Medical Center
• Contact: (Eline) P. Slagboom, Prof. dr.
• Phone: +31(0)71 5269 730
• Email: p.slagboom[@]lumc.nl
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The demographic life expectancy enhancement of the past 150 years imposes an urgent challenge in Western and economically growing societies to stimulate the healthy lifespan that is lagging behind. Families surviving into exceptionally high ages (longevity) in good physical and mental health illustrate that this is physiologically possible. Such families harbor cross generational socio-genetic mechanisms that mediate healthy aging and protection from (multi)morbidity.

The purpose of our research is: to identify gene variants associated with healthy aging and protection from (multi)morbidity; to study the social-, environment- and behavioral factors of familial longevity, their role in (multi-)morbidity and its interaction with the genetic component.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: December 2026
• Est. primary completion date: December 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 75 Years and older

Eligibility

Inclusion Criteria:

• Siblings of Dutch Caucasian descent age 75+ enriched for familial longevity

• Individuals of Dutch Caucasian descent age 75+ who are not enriched for familial longevity

Exclusion Criteria:

-

Related Conditions & MeSH terms

• Aging
• Extreme Longevity

Locations

Country	Name	City	State
Netherlands	Leiden University Medical Center	Leiden	South Holland

Sponsors (3)

Lead Sponsor	Collaborator
Leiden University Medical Center	Jacobijn Gussekloo, Prof. dr., Simon P. Mooijaart, Prof. dr.

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identifying the genetic variants of Familial Longevity	To identify gene variants associated with healthy aging and protection from (multi)morbidity	through study completion, an average of 2 years
Secondary	Studying the environmental factor of Familial Longevity through questionnaires and its interaction with the genetic component	To study the social-, environment- and behavioral factors of familial longevity, their role in (multi-)morbidity and its interaction with the genetic component	through study completion, an average of 2 years